Literature DB >> 1265438

Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG.

K B Jensen, S Jarnum, G Koudahl, M Kristensen.   

Abstract

Serum orosomucoid was compared with clinical activity, routine laboratory tests, intestinal protein loss, and albumin and IgG turnover in 22 cases of ulcerative colitis. Serum orosomucoid was well correlated with clinical activity, haemoglobin and leucocyte counts were not. A significant correlation was present between serum orosomucoid and intestinal protein loss (gastro-intestinal 59Fe-iron dextran clearance), serum albumin, fractional catabolic rates of albumin, and IgG and IgG synthesis rate. No correlation was found between serum orosomucoid and albumin synthesis rate or serum IgG. It is concluded that serum orosomucoid is a highly reliable indicator of disease activity in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1265438

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

Review 1.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

3.  Lamina propria eosinophils and mast cells in ulcerative colitis: comparison between Asians and Caucasians.

Authors:  G F Benfield; R Bryan; J Crocker
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

Review 4.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 5.  Assessment of drug therapy in inflammatory bowel disease.

Authors:  H J Hodgson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

6.  Clinical impact of colectomy and ileorectal anastomosis in the management of Crohn's disease.

Authors:  N S Ambrose; M R Keighley; J Alexander-Williams; R N Allan
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

7.  Effect of inflammatory bowel disease on absorption and disposition of prednisolone.

Authors:  R L Milsap; D E George; S J Szefler; K A Murray; E Lebenthal; W J Jusko
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

8.  Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management.

Authors:  N A Buckell; J E Lennard-Jones; M A Hernandez; J Kohn; P G Riches; J Wadsworth
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

Review 9.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

10.  Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease.

Authors:  N Arber; S Berliner; A Hallak; Y Bujanover; I Dotan; E Liberman; M Santo; M Moshkowitz; J Ratan; G Dotan
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.